NO20041075L - Ny 1, 2, 4-triazolforbindelse - Google Patents

Ny 1, 2, 4-triazolforbindelse

Info

Publication number
NO20041075L
NO20041075L NO20041075A NO20041075A NO20041075L NO 20041075 L NO20041075 L NO 20041075L NO 20041075 A NO20041075 A NO 20041075A NO 20041075 A NO20041075 A NO 20041075A NO 20041075 L NO20041075 L NO 20041075L
Authority
NO
Norway
Prior art keywords
new
triazole compound
triazole
compound
Prior art date
Application number
NO20041075A
Other languages
English (en)
Other versions
NO326941B1 (no
Inventor
Hiroshi Nakamura
Soichi Kaneda
Takahiro Sato
Naoki Ashizawa
Koji Matsumoto
Original Assignee
Fuji Yakuhin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Yakuhin Co Ltd filed Critical Fuji Yakuhin Co Ltd
Publication of NO20041075L publication Critical patent/NO20041075L/no
Publication of NO326941B1 publication Critical patent/NO326941B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20041075A 2002-01-28 2004-03-15 1,2,4-triazolforbindelse, medikament som omfatter forbindelsen, og anvendelse av forbindelsen for fremstilling av farmasoytisk sammensetning mot sykdom NO326941B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002017825 2002-01-28
PCT/JP2002/012662 WO2003064410A1 (en) 2002-01-28 2002-12-03 Novel 1,2,4-triazole compound

Publications (2)

Publication Number Publication Date
NO20041075L true NO20041075L (no) 2004-03-15
NO326941B1 NO326941B1 (no) 2009-03-16

Family

ID=27653386

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041075A NO326941B1 (no) 2002-01-28 2004-03-15 1,2,4-triazolforbindelse, medikament som omfatter forbindelsen, og anvendelse av forbindelsen for fremstilling av farmasoytisk sammensetning mot sykdom

Country Status (21)

Country Link
US (1) US7074816B2 (no)
EP (1) EP1471065B1 (no)
JP (1) JP3600832B2 (no)
CN (1) CN1561340B (no)
AR (1) AR042602A1 (no)
AT (1) ATE387438T1 (no)
AU (1) AU2002349754B2 (no)
BR (1) BRPI0212775B8 (no)
CA (1) CA2462132C (no)
DE (1) DE60225341T2 (no)
DK (1) DK1471065T3 (no)
ES (1) ES2300486T3 (no)
MX (1) MXPA04004037A (no)
NO (1) NO326941B1 (no)
NZ (1) NZ531673A (no)
PL (1) PL208260B1 (no)
PT (1) PT1471065E (no)
RU (1) RU2293733C2 (no)
TW (1) TWI257926B (no)
WO (1) WO2003064410A1 (no)
ZA (1) ZA200401777B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1826335A (zh) * 2003-07-24 2006-08-30 株式会社富士药品 1,2,4-三唑化合物的制造方法以及其中间体
US20060189811A1 (en) * 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2006121995A2 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
US7947707B2 (en) 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
KR20090031744A (ko) * 2006-06-22 2009-03-27 닛뽕 케미파 가부시키가이샤 항암제 내성 극복제
WO2008010315A1 (en) 2006-07-19 2008-01-24 Nippon Medical School Foundation Therapeutic agent for amyotrophic lateral sclerosis
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
BRPI0718611A2 (pt) * 2006-11-13 2014-02-25 Takeda Pharmaceuticals North America Inc Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase.
EP2120956A4 (en) * 2007-01-19 2010-01-20 Takeda Pharmaceuticals North A METHODS FOR PREVENTING OR REDUCING THE NUMBER OF DROUGHT ERYTHEMES USING XANTHINE OXYDOREDUCTASE INHIBITORS AND INFLAMMATORY AGENTS
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
DK2217577T3 (da) 2007-11-27 2014-10-20 Ardea Biosciences Inc Hidtil ukendte forbindelser og præparater og fremgangsmåder til anvendelse deraf
EP2165705A1 (en) 2008-09-18 2010-03-24 Centre National de la Recherche Scientifique (CNRS) Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
RU2412180C1 (ru) * 2009-07-29 2011-02-20 Государственное образовательное учреждение высшего профессионального образования "Южно-Российский государственный технический университет (Новочеркасский политехнический институт)" Способ получения 3(5)-пиридилзамещенных 5(3)-амино-1,2,4-триазолов
WO2012033941A1 (en) 2010-09-10 2012-03-15 Takeda Pharmaceuticals North America, Inc. Methods for concomitant treatment of theophylline and febuxostat
JP5862897B2 (ja) * 2010-11-01 2016-02-16 株式会社三和化学研究所 腎機能障害の予防又は治療に用いる医薬
WO2012081736A1 (en) 2010-12-17 2012-06-21 Mitsubishi Tanabe Pharma Corporation Continuous arycyclic compound
WO2012118485A1 (en) 2011-03-01 2012-09-07 Empire Technology Development Llc Temperature controlled variable reflectivity coatings
RU2476428C1 (ru) * 2011-09-01 2013-02-27 Государственное образовательное учреждение высшего профессионального образования "Южно-Российский государственный технический университет (Новочеркасский политехнический институт)" Способ получения дигидрохлорида 5-амино-3-аминометил-1,2,4-триазола
WO2013187496A1 (ja) 2012-06-15 2013-12-19 田辺三菱製薬株式会社 芳香族複素環化合物
RU2639149C2 (ru) 2012-07-25 2017-12-20 Фудзиякухин Ко., Лтд Кристаллический полиморф 4-[5-(пиридин-4-ил)-1н-1,2,4-триазол-3-ил]-пиридин-2-карбонитрила и способ его получения
CN104411686B (zh) 2012-07-25 2016-08-31 株式会社富士药品 4-[5-(吡啶-4-基)-1h-1,2,4-三唑-3-基]吡啶-2-腈的制造方法及中间体
CN103724329B (zh) * 2013-12-23 2015-02-18 济南百诺医药科技开发有限公司 4-[5-(吡啶-4-基)-1h-[1,2,4]三唑-3-基]吡啶-2-甲腈的制备方法
CN104042577B (zh) * 2014-06-13 2016-08-24 安徽省逸欣铭医药科技有限公司 一种稳定的托匹司他片及其制备方法
CN105315260A (zh) * 2014-07-29 2016-02-10 北京海步医药科技股份有限公司 一种托布司他一水合物晶型及其制备方法
CN105348264B (zh) * 2014-08-18 2018-01-16 上海医药工业研究院 一种托吡司他的合成方法
CN105367490B (zh) * 2014-08-18 2019-01-04 上海医药工业研究院 合成托吡司他的新中间体及其制备方法
CN104151297B (zh) * 2014-08-27 2016-03-16 王庆本 4-[5-(吡啶-4-基)-1h-[1,2,4]三唑-3-基]吡啶-2-甲腈的制备方法
JP6684264B2 (ja) * 2015-02-17 2020-04-22 株式会社三和化学研究所 心不全の予防又は治療のための医薬
WO2016136727A1 (ja) 2015-02-24 2016-09-01 国立大学法人鳥取大学 認知症の予防及び/又は治療のための医薬
WO2016134854A1 (en) 2015-02-25 2016-09-01 Pharmathen S.A. Methods for the preparation of topiroxostat and intermediates thereof
CN105693699B (zh) * 2015-03-30 2019-06-18 苏州晶云药物科技股份有限公司 托吡司他的晶型及其制备方法
CN104910068B (zh) * 2015-04-24 2017-07-14 南京医科大学 一种2‑氰基异烟酸酰肼1.5对甲苯磺酸盐的合成方法
CN106279111A (zh) * 2015-05-12 2017-01-04 北京济美堂医药研究有限公司 一种精制托吡司他的新方法
CN104961730B (zh) * 2015-06-18 2017-05-17 山东金城医药化工股份有限公司 托吡司他新晶型及其制备方法
CN105130958B (zh) * 2015-08-31 2017-10-31 济南康和医药科技有限公司 5‑(2‑氰基4‑吡啶基)‑3‑(4‑吡啶基)‑1,2,4‑三唑的制备工艺
CN105294656A (zh) * 2015-10-10 2016-02-03 大道隆达(北京)医药科技发展有限公司 一种托匹司他的制备工艺和方法
CN106336399A (zh) * 2015-11-03 2017-01-18 江苏悦兴药业有限公司 托匹司他工艺杂质的制备方法
CN105294584A (zh) * 2015-11-30 2016-02-03 中国医科大学 1-取代苯基-1h-1,2,3-三唑类化合物、制备方法及其用途
CN105399732A (zh) * 2015-12-07 2016-03-16 青岛正大海尔制药有限公司 一种托匹司他的制备方法
CN106008465A (zh) * 2016-03-16 2016-10-12 江苏悦兴药业有限公司 一种托匹司他杂质的合成方法
CN108250183A (zh) * 2016-12-29 2018-07-06 北京诚济制药有限公司 一种高纯度的托匹司他的制备方法
CN109721586B (zh) * 2017-10-27 2021-03-02 中国医科大学 一种5-苄基-3-吡啶基-1h-1,2,4-三唑类化合物及其制备方法和用途
CN107652271B (zh) * 2017-11-06 2020-06-16 上海中拓医药科技有限公司 一种托匹司他晶型i的制备方法
CN108017619B (zh) * 2017-12-06 2020-08-11 成都惟邦药业有限公司 一种托匹司他杂质及其制备方法
CN113354616B (zh) * 2020-03-05 2024-03-26 中国医学科学院药物研究所 二芳基-1,2,4-三唑类化合物及其制法和药物用途
CN113666909B (zh) * 2020-05-14 2024-07-02 鲁南制药集团股份有限公司 一种托匹司他的制备方法
CN114773262B (zh) * 2022-05-19 2024-05-07 兄弟科技股份有限公司 2-氰基-4-吡啶羧酸甲酯的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7112373A (no) * 1970-09-25 1972-03-28
US3947577A (en) * 1973-05-21 1976-03-30 Merck & Co., Inc. Anti-hyperuricemia composition
US3984558A (en) * 1973-05-21 1976-10-05 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds used as bronchodilators
US3928361A (en) * 1973-05-21 1975-12-23 Merck & Co Inc 1-(Sulfamoylphenylalkyl)-3,5-dipyridyl-1,2,4 triazoles
US3963731A (en) * 1973-05-21 1976-06-15 Merck & Co., Inc. Pyridyl containing 1-benzenesulfonyl triazoles
US3882134A (en) * 1973-05-21 1975-05-06 Merck & Co Inc 1-Substituted-3,5-dipyridyl-1,2,4-triazoles
US4104393A (en) * 1976-04-02 1978-08-01 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds
WO1993011433A1 (en) * 1991-12-05 1993-06-10 Wallac Oy Luminescent lanthanide chelates
JP3217846B2 (ja) * 1992-03-04 2001-10-15 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫剤
AU1130700A (en) * 1998-10-23 2000-05-15 Dow Agrosciences Llc Insecticidal 1-(substituted pyridyl)-1,2,4-triazoles
KR100838447B1 (ko) * 2001-02-21 2008-06-16 아스트라제네카 아베 헤테로폴리시클릭 화합물 및 대사향성 글루타메이트수용체 길항제로서의 그의 용도

Also Published As

Publication number Publication date
ES2300486T3 (es) 2008-06-16
JP3600832B2 (ja) 2004-12-15
RU2293733C2 (ru) 2007-02-20
ATE387438T1 (de) 2008-03-15
CN1561340B (zh) 2012-05-23
HK1067132A1 (en) 2005-04-01
EP1471065A1 (en) 2004-10-27
CA2462132C (en) 2010-08-10
WO2003064410A1 (en) 2003-08-07
RU2004106554A (ru) 2005-07-27
BRPI0212775B1 (pt) 2017-06-06
DK1471065T3 (da) 2008-03-25
AR042602A1 (es) 2005-06-29
AU2002349754B2 (en) 2008-01-31
EP1471065B1 (en) 2008-02-27
PL368672A1 (en) 2005-04-04
BR0212775A (pt) 2004-10-13
TW200302222A (en) 2003-08-01
ZA200401777B (en) 2005-08-31
TWI257926B (en) 2006-07-11
NO326941B1 (no) 2009-03-16
DE60225341D1 (de) 2008-04-10
CA2462132A1 (en) 2003-08-07
EP1471065A4 (en) 2005-06-15
NZ531673A (en) 2006-06-30
PL208260B1 (pl) 2011-04-29
CN1561340A (zh) 2005-01-05
US20050004175A1 (en) 2005-01-06
MXPA04004037A (es) 2004-07-23
PT1471065E (pt) 2008-03-13
US7074816B2 (en) 2006-07-11
DE60225341T2 (de) 2009-04-09
BRPI0212775B8 (pt) 2021-05-25
JPWO2003064410A1 (ja) 2005-05-26

Similar Documents

Publication Publication Date Title
NO20041075L (no) Ny 1, 2, 4-triazolforbindelse
CY2014041I1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
DE602004006169D1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
IS6971A (is) Ný efnasambönd
DE60216115D1 (de) BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
IS7471A (is) Ný efnasambönd
ATE402152T1 (de) Hiv-inhibierende1,2,4-triazine
IS7879A (is) Ný efnasambönd
ATE326467T1 (de) Imidazo 1,2-aöpyridine
IS7793A (is) Nýtt efnasamband
IS7794A (is) Nýtt efnasamband
IS7827A (is) Ný efnasambönd
DE60315471D1 (de) 2,5-disubstituierte 3-mercaptopentansaure
DK1487778T3 (da) Substituerede 4 aminocyclohexanoler
NO20044405L (no) Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
ATE470655T1 (de) Substituierte 1,5-diaminopentan-3-ol-verbindungen
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
DE60224192D1 (de) Antihaemorrhagische, betain-enthaltende zusammenseuzungen
SE0202007D0 (sv) New compound
SE0301847D0 (sv) Novel 3,3-Diphenylpropylamines
DE60327989D1 (de) Quarternäre imidazolinverbindungen
IS7299A (is) 3,4-díhýdró-1H-ísókínólóín-2-ýl-afleiður
SE0100629D0 (sv) New compounds
SE0101660D0 (sv) New compounds
SE0104342D0 (sv) New compounds

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees